Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • APR 19 2016

    Computer to clinic: Tool developed at Weill predicts drug success

    Weill Cornell Medical College highlights the collaboration between Oncoceutics and the lab of Dr. Olivier Elemento, which used a computer algorithm developed in Dr. Elemento’s lab to predict the interaction between ONC201 and Dopamine Receptor 2, which was later validated by Oncoceutics. Computer to clinic: Tool developed at Weill predicts drug success

    • MAR 24 2016

    Oncoceutics Highlighted by German American Chamber of Commerce of Philadelphia

    The following article appeared in the March 2016 Member Newsletter of the German American Chamber of Commerce, Philadelphia Oncoceutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of highly differentiated treatments for difficult cancers. The company was founded in 2009 by GACC member Wolfgang Oster, Lee Schalop, and scientific founder Wafik